AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCERamakrishna K
An introduction to pharmacovigilance, basic types like active pharmacovigilance and passive pharmacovigilance, purpose, adverse event reporting, data processing, causality, assessement, signal detection, risk management plans and analysis
Pharmacovigilance Process Work Flow - Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance Process Work Flow for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
AN OVERVIEW AND IMPORTANCE OF PHARMACOVIGILANCERamakrishna K
An introduction to pharmacovigilance, basic types like active pharmacovigilance and passive pharmacovigilance, purpose, adverse event reporting, data processing, causality, assessement, signal detection, risk management plans and analysis
Pharmacovigilance Process Work Flow - Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance Process Work Flow for Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.
a presentation in CME activities by Saad Specialist Hospital, KSA
- Whilst the realization of the CTD took many years, there is now a common format for the submission of Marketing Authorizations Applications across the three ICH regions - Europe, Japan and the USA.
- This should facilitate pharmaceutical companies to make simultaneous filings in the ICH regions as it will eliminate the extensive work previously required to convert, for example, a US dossier to an EU dossier and vice versa.
pharmacovigilance, adverse effects, causality assessment,methods, who-umc method with case study, FOR DOWNLOAD PPT MAIL ME ON iamgauravchhabra@gmail.com
Pharmacovigilanc: The science & activities relating to the Detection, Assessment, Understanding and Prevention of adverse effects or any other drug related problems
The Thalidomide Tragedy (Lessons for Drug Safety and Regulation)
CLASSIFICATION OF ADRS (RAWLIN AND THOMPSON CLASSIFICATION)
Why PV is Necessary?
Objective of PV
Outcomes of Drugs
Causal Relationship
Adverse drug reaction and causality assessment scales
Classification of AE
Serious Adverse Event (SAE)
Sources of Adverse Events (AE) reports
Sources of AE Reports(Solicited Reports)
What to Report?
Who to Report?
When to Report?
Individual case data flow
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Basic aspects of Pharmacovigilance (Clinical Research & Pharmacovigilance).pptxDureshahwar khan
The slides in this presentation mainly focus on History and Progress of Pharmacovigilance, significance of safety monitoring and Pharmacovigilance in India & International aspects.
Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem.
a presentation in CME activities by Saad Specialist Hospital, KSA
- Whilst the realization of the CTD took many years, there is now a common format for the submission of Marketing Authorizations Applications across the three ICH regions - Europe, Japan and the USA.
- This should facilitate pharmaceutical companies to make simultaneous filings in the ICH regions as it will eliminate the extensive work previously required to convert, for example, a US dossier to an EU dossier and vice versa.
pharmacovigilance, adverse effects, causality assessment,methods, who-umc method with case study, FOR DOWNLOAD PPT MAIL ME ON iamgauravchhabra@gmail.com
Pharmacovigilanc: The science & activities relating to the Detection, Assessment, Understanding and Prevention of adverse effects or any other drug related problems
The Thalidomide Tragedy (Lessons for Drug Safety and Regulation)
CLASSIFICATION OF ADRS (RAWLIN AND THOMPSON CLASSIFICATION)
Why PV is Necessary?
Objective of PV
Outcomes of Drugs
Causal Relationship
Adverse drug reaction and causality assessment scales
Classification of AE
Serious Adverse Event (SAE)
Sources of Adverse Events (AE) reports
Sources of AE Reports(Solicited Reports)
What to Report?
Who to Report?
When to Report?
Individual case data flow
Drug Safety & Pharmacovigilance - Introduction - Katalyst HLSKatalyst HLS
Introduction to Drug Safety & Pharmacovigilance in Pharmaceuticals, Bio-Pharmaceuticals, Medical Devices, Cosmeceuticals and Foods.
Contact:
"Katalyst Healthcares & Life Sciences"
South Plainfield, NJ, USA
info@KatalystHLS.com
Basic aspects of Pharmacovigilance (Clinical Research & Pharmacovigilance).pptxDureshahwar khan
The slides in this presentation mainly focus on History and Progress of Pharmacovigilance, significance of safety monitoring and Pharmacovigilance in India & International aspects.
Regulations for drug approval in USA, E.U & India
Pharmaceutical industry is the most regulated of all the industries. Regulations are put in order to develop the most efficient and safe pharmaceutical products. It takes more than 8 to 15 years to develop a new drug product & costs more than $ 800 million.
Introduction to Pharmacovigilance
History and development of Pharmacovigilance
Importance of safety monitoring of Medicine
WHO international drug monitoring programme
Pharmacovigilance Program of India(PvPI)
Pharmacovigilance is the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problems. It plays a crucial role in ensuring the safety and proper use of medications throughout their lifecycle, from pre-marketing clinical trials to post-marketing surveillance.
The primary objectives of pharmacovigilance are:
Adverse Drug Reaction (ADR) Detection: Pharmacovigilance aims to detect and identify adverse reactions or unexpected side effects associated with medications. This involves collecting and analyzing data from various sources, including healthcare professionals, patients, clinical trials, and scientific literature.
ADR Assessment and Causality Evaluation: Once an adverse event is reported, pharmacovigilance professionals assess its severity, clinical presentation, and potential causality with the medication. This evaluation helps determine the relationship between the drug and the reported event.
Risk-Benefit Assessment: Pharmacovigilance assesses the balance between the benefits and risks of medications. This involves evaluating the available safety data, clinical trial results, real-world evidence, and other relevant information to ensure that the benefits of a medication outweigh its potential risks.
Signal Detection and Management: Pharmacovigilance monitors for potential safety signals, which are new or changing patterns of adverse events or safety concerns related to a specific medication. Signals are detected through data analysis, signal detection algorithms, and data mining techniques. Once identified, signals are further evaluated, validated, and managed appropriately.
Regulatory Compliance: Pharmacovigilance ensures compliance with regulatory requirements and guidelines related to drug safety monitoring. It involves timely reporting of adverse events to regulatory authorities, submission of periodic safety reports, and adherence to pharmacovigilance obligations set by regulatory agencies.
Risk Minimization and Communication: Pharmacovigilance plays a role in developing risk minimization strategies to mitigate the identified risks associated with medications. It involves providing accurate and up-to-date safety information to healthcare professionals, patients, and the public through drug labeling updates, educational materials, and communication campaigns.
Benefit-Risk Communication: Pharmacovigilance supports the communication of the benefit-risk profile of medications to healthcare professionals, regulatory authorities, patients, and other stakeholders. This facilitates informed decision-making and helps ensure the safe and effective use of medications.
Pharmacovigilance activities are conducted by pharmaceutical companies, regulatory agencies, healthcare professionals, and other stakeholders involved in drug development, distribution, and monitoring. These activities contribute to the ongoing evaluation and improvement of drug safety
ADR reporting (Clinical Research & Pharmacovigilance).pptxDureshahwar khan
The content here, include passive surveillance system, ADR reporting, ADR reporting process, different countries ADR reporting systems, what to report?, how to report?, where to report?, Health professionals are encouraged to report adverse reactions which they believe to be drug related directly to The regulatory authority or The company marketing the suspected product on voluntary basis.
PHARMACOVIGILANCE - A Worldwide masterkey for Drug MonitoringVenugopal N
Pharmacovigilance is the pharmacological science that aims at the detection, assessment, monitoring, understanding and prevention of adverse effects, particularly long term and short term side effects of medicines to ensure drug safety.
Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy and banking.
Regulatory Affairs (RA), also called Government Affairs, is a profession within regulated industries, such as pharmaceuticals, medical devices, energy and banking.
History of regulatory affair. Various Regulatory Authority. Role of Regulatory Affairs Department.
Pre-clinical or Non- clinical phase of drug development . Investigational New Drug Application (IND) Importance of IND. Investigator’s Brochure (IB). The Investigator’s Brochure (IB) is a compilation of the clinical and nonclinical data on the investigational product(s) that are relevant to the study of the product(s) in human subjects. A complete and thorough investigator’s brochure should include the following: Title Page
I. A] Confidentiality Statement
II. Contents of the Investigator’s Brochure
II. A] Table of Contents
II. B] Summary
II. C] Introduction
II. D] Physical, Chemical, and Pharmaceutical Properties and
Formulation
II. E] Nonclinical Studies
II. F] Effects in Humans
II. G] Summary of Data and Guidance for the Investigator. Contents of the Investigator’s Brochure: II. A] Table of Contents
II. B] Summary:
Not longer than 2 pages.
Highlighting significant physical, chemical, pharmaceutical, pharmacological, toxicological, pharmacokinetic, metabolic and clinical information available that is relevant to the state of clinical development of the investigational product. II. D] Physical, Chemical, and Pharmaceutical Properties
and Formulation:
A description of the investigational product substances including the chemical and or structural formulae and the brief summary of the relevant physical, chemical and pharmaceutical properties.
For safety measures, a description of the formulations to be used including excipients (a substance formulated with the active ingredient of a medication) should be provided and justified if clinically relevant.
Instructions for the storage and handling of the dosage should be provided.
Structural similarities to other known compounds should be mentioned. Pharmacokinetics and Product Metabolism in Humans
A summary of information on the pharmacokinetics of the investigational product(s) should be presented, including the following, if available:
Pharmacokinetics (including metabolism, as appropriate, and absorption, plasma protein binding, distribution and elimination).
Bioavailability of the investigational product (absolute, where possible, and/or relative) using a reference dosage form.
Population subgroups (e.g. gender, age, and impaired organ function).
Interactions (e.g. product-product interactions and effects of food).
Other pharmacokinetic data (e.g. results of population studies performed within clinical trial(s). . Marketing Experience
The Investigator’s Brochure should identify countries where the investigational product has been approved.
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other medicine/vaccine related problem.
India Clinical Trials Market: Industry Size and Growth Trends [2030] Analyzed...Kumar Satyam
According to TechSci Research report, "India Clinical Trials Market- By Region, Competition, Forecast & Opportunities, 2030F," the India Clinical Trials Market was valued at USD 2.05 billion in 2024 and is projected to grow at a compound annual growth rate (CAGR) of 8.64% through 2030. The market is driven by a variety of factors, making India an attractive destination for pharmaceutical companies and researchers. India's vast and diverse patient population, cost-effective operational environment, and a large pool of skilled medical professionals contribute significantly to the market's growth. Additionally, increasing government support in streamlining regulations and the growing prevalence of lifestyle diseases further propel the clinical trials market.
Growing Prevalence of Lifestyle Diseases
The rising incidence of lifestyle diseases such as diabetes, cardiovascular diseases, and cancer is a major trend driving the clinical trials market in India. These conditions necessitate the development and testing of new treatment methods, creating a robust demand for clinical trials. The increasing burden of these diseases highlights the need for innovative therapies and underscores the importance of India as a key player in global clinical research.
We understand the unique challenges pickleball players face and are committed to helping you stay healthy and active. In this presentation, we’ll explore the three most common pickleball injuries and provide strategies for prevention and treatment.
The dimensions of healthcare quality refer to various attributes or aspects that define the standard of healthcare services. These dimensions are used to evaluate, measure, and improve the quality of care provided to patients. A comprehensive understanding of these dimensions ensures that healthcare systems can address various aspects of patient care effectively and holistically. Dimensions of Healthcare Quality and Performance of care include the following; Appropriateness, Availability, Competence, Continuity, Effectiveness, Efficiency, Efficacy, Prevention, Respect and Care, Safety as well as Timeliness.
Welcome to Secret Tantric, London’s finest VIP Massage agency. Since we first opened our doors, we have provided the ultimate erotic massage experience to innumerable clients, each one searching for the very best sensual massage in London. We come by this reputation honestly with a dynamic team of the city’s most beautiful masseuses.
CHAPTER 1 SEMESTER V - ROLE OF PEADIATRIC NURSE.pdfSachin Sharma
Pediatric nurses play a vital role in the health and well-being of children. Their responsibilities are wide-ranging, and their objectives can be categorized into several key areas:
1. Direct Patient Care:
Objective: Provide comprehensive and compassionate care to infants, children, and adolescents in various healthcare settings (hospitals, clinics, etc.).
This includes tasks like:
Monitoring vital signs and physical condition.
Administering medications and treatments.
Performing procedures as directed by doctors.
Assisting with daily living activities (bathing, feeding).
Providing emotional support and pain management.
2. Health Promotion and Education:
Objective: Promote healthy behaviors and educate children, families, and communities about preventive healthcare.
This includes tasks like:
Administering vaccinations.
Providing education on nutrition, hygiene, and development.
Offering breastfeeding and childbirth support.
Counseling families on safety and injury prevention.
3. Collaboration and Advocacy:
Objective: Collaborate effectively with doctors, social workers, therapists, and other healthcare professionals to ensure coordinated care for children.
Objective: Advocate for the rights and best interests of their patients, especially when children cannot speak for themselves.
This includes tasks like:
Communicating effectively with healthcare teams.
Identifying and addressing potential risks to child welfare.
Educating families about their child's condition and treatment options.
4. Professional Development and Research:
Objective: Stay up-to-date on the latest advancements in pediatric healthcare through continuing education and research.
Objective: Contribute to improving the quality of care for children by participating in research initiatives.
This includes tasks like:
Attending workshops and conferences on pediatric nursing.
Participating in clinical trials related to child health.
Implementing evidence-based practices into their daily routines.
By fulfilling these objectives, pediatric nurses play a crucial role in ensuring the optimal health and well-being of children throughout all stages of their development.
Medical Technology Tackles New Health Care Demand - Research Report - March 2...pchutichetpong
M Capital Group (“MCG”) predicts that with, against, despite, and even without the global pandemic, the medical technology (MedTech) industry shows signs of continuous healthy growth, driven by smaller, faster, and cheaper devices, growing demand for home-based applications, technological innovation, strategic acquisitions, investments, and SPAC listings. MCG predicts that this should reflects itself in annual growth of over 6%, well beyond 2028.
According to Chris Mouchabhani, Managing Partner at M Capital Group, “Despite all economic scenarios that one may consider, beyond overall economic shocks, medical technology should remain one of the most promising and robust sectors over the short to medium term and well beyond 2028.”
There is a movement towards home-based care for the elderly, next generation scanning and MRI devices, wearable technology, artificial intelligence incorporation, and online connectivity. Experts also see a focus on predictive, preventive, personalized, participatory, and precision medicine, with rising levels of integration of home care and technological innovation.
The average cost of treatment has been rising across the board, creating additional financial burdens to governments, healthcare providers and insurance companies. According to MCG, cost-per-inpatient-stay in the United States alone rose on average annually by over 13% between 2014 to 2021, leading MedTech to focus research efforts on optimized medical equipment at lower price points, whilst emphasizing portability and ease of use. Namely, 46% of the 1,008 medical technology companies in the 2021 MedTech Innovator (“MTI”) database are focusing on prevention, wellness, detection, or diagnosis, signaling a clear push for preventive care to also tackle costs.
In addition, there has also been a lasting impact on consumer and medical demand for home care, supported by the pandemic. Lockdowns, closure of care facilities, and healthcare systems subjected to capacity pressure, accelerated demand away from traditional inpatient care. Now, outpatient care solutions are driving industry production, with nearly 70% of recent diagnostics start-up companies producing products in areas such as ambulatory clinics, at-home care, and self-administered diagnostics.
Defecation
Normal defecation begins with movement in the left colon, moving stool toward the anus. When stool reaches the rectum, the distention causes relaxation of the internal sphincter and an awareness of the need to defecate. At the time of defecation, the external sphincter relaxes, and abdominal muscles contract, increasing intrarectal pressure and forcing the stool out
The Valsalva maneuver exerts pressure to expel faeces through a voluntary contraction of the abdominal muscles while maintaining forced expiration against a closed airway. Patients with cardiovascular disease, glaucoma, increased intracranial pressure, or a new surgical wound are at greater risk for cardiac dysrhythmias and elevated blood pressure with the Valsalva maneuver and need to avoid straining to pass the stool.
Normal defecation is painless, resulting in passage of soft, formed stool
CONSTIPATION
Constipation is a symptom, not a disease. Improper diet, reduced fluid intake, lack of exercise, and certain medications can cause constipation. For example, patients receiving opiates for pain after surgery often require a stool softener or laxative to prevent constipation. The signs of constipation include infrequent bowel movements (less than every 3 days), difficulty passing stools, excessive straining, inability to defecate at will, and hard feaces
IMPACTION
Fecal impaction results from unrelieved constipation. It is a collection of hardened feces wedged in the rectum that a person cannot expel. In cases of severe impaction the mass extends up into the sigmoid colon.
DIARRHEA
Diarrhea is an increase in the number of stools and the passage of liquid, unformed feces. It is associated with disorders affecting digestion, absorption, and secretion in the GI tract. Intestinal contents pass through the small and large intestine too quickly to allow for the usual absorption of fluid and nutrients. Irritation within the colon results in increased mucus secretion. As a result, feces become watery, and the patient is unable to control the urge to defecate. Normally an anal bag is safe and effective in long-term treatment of patients with fecal incontinence at home, in hospice, or in the hospital. Fecal incontinence is expensive and a potentially dangerous condition in terms of contamination and risk of skin ulceration
HEMORRHOIDS
Hemorrhoids are dilated, engorged veins in the lining of the rectum. They are either external or internal.
FLATULENCE
As gas accumulates in the lumen of the intestines, the bowel wall stretches and distends (flatulence). It is a common cause of abdominal fullness, pain, and cramping. Normally intestinal gas escapes through the mouth (belching) or the anus (passing of flatus)
FECAL INCONTINENCE
Fecal incontinence is the inability to control passage of feces and gas from the anus. Incontinence harms a patient’s body image
PREPARATION AND GIVING OF LAXATIVESACCORDING TO POTTER AND PERRY,
An enema is the instillation of a solution into the rectum and sig
Telehealth Psychology Building Trust with Clients.pptxThe Harvest Clinic
Telehealth psychology is a digital approach that offers psychological services and mental health care to clients remotely, using technologies like video conferencing, phone calls, text messaging, and mobile apps for communication.
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
2. It is the pharmacological science relating to the collection, detection,
assessment, monitoring and prevention of Adverse reactions with
Pharmaceutical products
Pharmacovigilance – Drug Safety
Pharmacovigilance
3. Objectives of Pharmacovigilance
To improve patients care and safety
To improve Public health and safety
To contribute to the assessment of benefit,
harm, effectiveness and risk of medicines
To promote understanding clinical
training & effective communication to
health professionals and public
6. •In 1848, a year after the Scottish surgeon Sir James Simpson
had discovered that chloroform was a safer and more
powerful anesthetic than ether.
•Hannah Greener a healthy 15 year-old girl from the north of
England became the first recorded fatality directly attributed to
chloroform.
• She required the removal of a second toenail, several months
after she had undergone a successful similar operation with
diethyl ether as the anesthetic.
•Two minutes after the start of the operation she was dead.
•The exact cause has been variously suggested, from an
anesthetic overdose to secondary complications
Hannah’s death
7. The causes of death was investigated to understand what happened to Hannah, but it was
impossible to identify what killed her.
As a result of other deaths and alerts raised by the clinicians and the public about the
safety of anesthesia, The Lancet Journal established a commission to take on this
problem.
The commission exhorted English doctors, including the doctor in colonies, to report
deaths caused by the anesthesia.
The results were published in The Lancet in 1893.
The US Federal FDA was formed on June 30, 1906, and it established that drugs must be
pure and free of any contamination.
Furthermore, in 1911, this organization forbade false therapeutic indications of drugs
8. Sulfanilamide
During September and October 1937 this drug was responsible for the deaths of more than 100 people
in 15 states, as far east as Virginia and as far west as California. The drug and the deaths led to the
passage of the 1938 Food, Drug, and Cosmetic Act, which increased FDA's authority to regulate
drugs.
Sulfanilamide- to treat Streptococcal infection
In June 1937 sudden
demand for the drug in
liquid form.
Companies
chief chemist
& pharmacist
found that
sulfanilamide
would dissolve
in diethylene
glycol
they tested it for flavor,
appearance, fragrance and
found it satisfactory and
shipped it all over the
country
New formulation had
not been tested for
toxicity.
9. At the time the food and drugs law did not require that safety studies be done on new drugs.
Watkins failed to note one characteristic of the solution.
Diethylene glycol, a chemical normally used as an antifreeze, is a deadly poison.
October 11 American Medical Association received reports from physicians – that Sulfanilamide was
responsible for number of deaths.
AMA asked for sample and found diethylene glycol as toxic ingredient and issued warning in newspaper
and radio.
1938 -Federal Food, Drug, and Cosmetic Act- The
New Drug section, added to prevent such tragedies,
gave the United States a new system of drug control
which provided superior protection while stimulating
medical research and progress
10. • In 1938, Douthwaite supposed that acetylsalicylic acid (ASA) could cause melena.
•In 1955, it was proved that ASA can cause GI diseases and therefore it is currently contraindicated in
patients with gastrointestinal ulcers
•In 1961, a big change of European Pharmacovigilance happened following the tragedy of
Thalidomide.
•Dr. McBride, an Australian doctor, wrote a letter to the editor of the Lancet Journal, in which he
suggested a connection between congenital malformation of babies and thalidomide.
•At the same time, during a Pediatric Convention in Germany Dr. Lenz suggested a correlation between
malformations and thalidomide and his suspect was published in a German Journal (Welt am Sonnatag)
•In USA, the tragedy of thalidomide was not observed, because Dr. Kelsey showed strong doubts about
the safety of thalidomide during pregnancy
11. Thalidomide tragedy – Lessons for Drug safety and regulation
•Thalidomide – initially prescribed to pregnant
women as tranquilizer and antiemetic for morning
sickness
•10,00.0 children worldwide are disabled.
•Developed by german pharmaceutical company
Grunenthal in stolberg
•first entered the German market in 1957 as an over-
the-counter remedy
12. The tragedy of thalidomide brought to light many problems and critical issues, in
particular, the reliability of animal tests, the behavior of the industrial company, and the
importance of monitoring the drugs after their marketing.
In particular, this tragedy changes the system of Pharmacovigilance, because the
spontaneous reporting of adverse drug reactions became systematic, organized, and
regulated.
This letter already contained all of the elements needed to generate a spontaneous
reporting and to establish a cause-effect relationship between the adverse event and the
drug
14. •In 1964, the “Yellow card” (YC) was structured in the UK.
•YC is a specific form to compile a spontaneous report of drug toxicity.
•In USA (1962), the amendment, requiring safety and efficacy data of drugs before premarketing submission,
was approved.
•In Europe (1965), the disaster of thalidomide stimulated the development of a European legislation with the EC
Directive 65/65.
•In 1966, a pilot study of Boston Collaborative Drug Surveillance Program started.
•It was the first group to conduct epidemiologic researches to quantify the potential adverse effects of drugs.
•In 1968, the WHO Programme for International Drug Monitoring was instituted and ten members participated
in this program (Australia, UK, USA, Germany, Canada, Ireland, Sweden, Denmark, New Zealand, and
Netherlands)
•Many studies of observed adverse drug reactions were conducted between 1968 and 1982
15. •In 1992, the European Society of Pharmacovigilance (ESoP) was funded, turned into the International
Society of Pharmacovigilance (IsoP).
•The aims of this society were to promote Pharmacovigilance, and enhance all aspects of the safe and
proper use of medicines
•In 1995, the European Medicines Agency (EMA) was set up.
•In 2001, EudraVigilance was funded.
•It is the official European database for managing and analyzing information on suspected adverse
reactions to medicines which have been authorized for the market or being studied in European clinical
trials,
•In November 2017, the new EudraVigilance format was launched; in particular, the marketing
authorizations will have extended access to the EudraVigilance database to support the fulfillment of
their Pharmacovigilance obligations
16. Pharmacovigilance in India
1986
ADR monitoring
system for India
(proposed in 12
regional centres)
1997
India joined WHO-
ADR monitoring
programme (3
centres: AIIMS,
KIM, JLN)
2010
Pharmacovigilance
programme of India
2004-2008
National
Pharmacovigilance
programme (2 zonal,
5 Regional, 24
Peripheral) overseen
by CDSCO
17. Terminology
Adverse Drug Reaction (ADR): An unintended reaction to a drug taken at doses normally used in man
Adverse Event (AE): Any untoward medical occurrence that may present during treatment with a
medicine but which does not necessarily have a causal relationship with the treatment
Serious Adverse Event (SAE) : Any AE which is fatal, life threatening, Congenital anomaly, permanently
disabling or which leads to hospitalization
Suspected Unexpected Serious Adverse Reaction (SUSAR): refer to an adverse event that occurs in a
clinical trial subject, which is assessed by the sponsor and or study investigator as being unexpected,
serious and as having a reasonable possibility of a causal relationship with the study drug.
18. Severity of ADR
Minor – No need of therapy/hospitalization
Moderate – Requires drug change
Severe – Life threatening, Hospitalization
Lethal – Leads to death
19. Pharmacovigilance process
Detecting and reporting an ADR
ADR form is filled out with patient and reaction
details in prescribed format – forms basis for data
entry
Reporting
Spontaneous Mandatory
•Most common form of
ADR reporting
•Health care
professionals identify and
report any suspected
ADR to national PV
centers/to the
manufacturers
•Manufactures are
required to submit
reports they receive from
health care providers to
the National authority in
the form of PSUR
(Periodic Safety update
Report)
•Regulatory document
prepared by marketing
authorization holder and
submitted to the agency
20. ADR reporting through vigiflow
Vigiflow is a web-based Individual Case Safety Report (ICSR) management system that
is specially designed for use by national centers in WHO programme for international drug
monitoring
Subscription for Vigiflow is free in India
ADR reporting forms
India (Red form), US (MED WATCH Form 3500), and UK (Yellow card
form)
Online Reporting systems:
India – Vigiflow
US – US online reporting
UK – Yellow card online reporting
21.
22.
23. Methods of collecting ADR
Comparative Observational
Studies
Cross sectional Survey
Case Control Study
Cohort Studies
Large Safety trials
Drug utilization studies
Active Surveillance
Site Surveillance (Hospitals,
Pharmacies, nursing homes etc.,)
Focused ADR monitoring of drugs
Prescription event monitoring
Disease registries from public
health record
24. Criteria for ADR and its Reporting to Regulatory
Authority
What to report?
Following events can be reported to the nearest reporting centre or authority
• Life-threatening event or death
• Hospitalization of the patient
• Congenital anomaly
• Lack of efficacy connected with the use of a medical device or drug product.
• All suspected drug interactions
All known or unknown, serious, non-serious, frequent or rare reaction caused due to use of vaccine or drug
must be reported.
25. When to report?
All spontaneous case should be reported within
10 days.
➢ All suspected ADR should be reported as
soon as possible because over reporting is
always better than under reporting.
➢ Death event must be reported as soon as
possible, while all other serious ADR/event
needs to report within 7 days only.
➢ All non-serious cases must be reported
within 30 days.
Who can report?
26. How to report?
Duly filled ADR reporting form needs to
send to the nearest AMC or directly to the NCC.
Dial toll free helpline number-1800 180 3024
to report ADRs.
Mailing the filled ADR reporting form directly
to pvpi@ipcindia.net or
pvpi.ipcindia@gmail.com.
Logging on to the http://www.ipc.gov.in,
http://www.ipc.gov.in/PvPI/pv_home.html for
list of authorized AMCs of India.
PVPI- Pharmacovigilace
programme of India
Where to report?
Various Peripheral, Regional and Zonal centers
have been proposed and established in India
WHO & UMC (Uppsala Monitoring Centre)- is
responsible for the management of WHO program
for International Drug monitoring
Computer software for case report management
is designed to suit the needs of National centers
( Vigiflow)
33. Roles and Responsibilities of In-Charge Personnel at PVPI
➢ The Co-ordinator at PVPI-AMC smooth and effective functioning of AMC.
➢ AMC appoints a technical associate who is responsible for collection, follow up, reporting,
scrutiny, assessment and entry of ADR in to Vigi-Flow database. All the procedure followed as per
SOP and final assessment is performed by NCC.
➢ AMC controller/in-charge %send monthly ADR status reports to NCC.
➢ Making awareness and guiding the HCPs, students, patients about ADR reporting by taking
lectures, advertisement though email, telephone, pamphlet and newsletter
➢ Feedback collection and communication to the HCPs is an additional duty of AMC coordinator.
35. Signal Detection
What Is A Signal
Information that arises from one or multiple sources (including observations and experiments), which suggests
a new potentially causal association, or a new aspect of a known association, between an intervention and an
event or set of related events, either adverse or beneficial, that is judged to be of sufficient likelihood to justify
verificatory action”.
Signal Detection
Signal detection in PV involves looking at the adverse reaction data for patterns that suggest new safety
information.
36. Process for managing signals
Signal detection
Validation and Confirmation
Analysis
Prioritization
Assessment
Recommending action
37. Causality Assessment
Causality assessment of ADRs is a method used for estimating the strength of relationship between
drug exposure and occurrence of adverse reaction.
It is an essential part of ADR report and important task conducted by National pharmacological
programme in each country.
Many regulatory authorities assess spontaneous ADR reports, where causality assessment can help in
signal detection and risk–benefit decisions regarding medicines.
38. Criteria for establishing causality
a) assessment of strength of the association,
b) consistency of the association,
c) specificity,
d) temporal relationship,
e) biological gradient (dose response),
f) biological plausibility,
g) coherence,
h) experimental evidence and
i) reasoning by analogy.
These elements of assessing strength of relationship between exposure (drugs) and
outcome (adverse reaction) are used widely in ADR CATs
41. Naranjo algorithm
Naranjo Scale is a questionnaire for determining the likelihood of whether an ADR is actually
due to the drug rather than the result of other factors.
Probability is assigned via a score termed definite, probable, possible or doubtful. Values
obtained from this algorithm are sometimes used in peer reviews to verify the validity of author's
conclusions regarding adverse drug reactions.
43. Individual Case Safety Report (ICSR)
Individual Case Safety Report is a document in a specific format for the reporting of one or several
suspected AR to a medicinal product that occur in a single patient at a specific point of time.
A WHO global individual case safety report database (VigiBase) is maintained and developed on behalf
of the WHO by the UMC.
VigiBase
VigiBase is the single largest drug safety data repository in the world.
Vigibase is used to obtain the information about a safety profile of a medicinal product.
These data are used by pharmaceutical industries, academic institutions and regulatory authorities for
statistical signal detection, updating periodic reports, ICSR comparisons with company databases and
studying the reporting patterns.
The data is collected from each of its 110 member states. About a hundred thousand ICSRs are added
each year.
44. Adverse event reporting
One of the fundamental principles of adverse event reporting is the determination of what
constitutes an ICSR. During the triage phase of a potential adverse event report, it is important
to determine if the “four elements” of a valid ICSR are present:
an identifiable patient
an identifiable reporter (called the “verbatim”)
a suspect drug
an adverse event
45. ICSR format is precise, exact and includes:
References for administration and identification purposes, including where the report came from and
who received it
All information from primary sources
Characteristics of the patient concerned
Description of the relevant events
Results of clinical tests and procedures
Characteristics of the medicinal product in question
Narrative style summary of the case
Any further relevant supporting information
46. It is expected that each ICSR should be:
Validated before reporting
Submitted within extremely strict and rapid timescales
Rapidly re-submitted as new or updated information becomes available which has an
impact on the original submission
You also need to be sure that detailed Safety Data Exchange Agreements (SDEAs)
exist regarding relevant information exchanges (including information from periodic
Literature Searching) with any of your contractors. SDEAs must be formulated to
ensure compliance with the interim and final arrangements.
47. The processing of individual case safety
reports (ICSRs) originating from various
sources:
•Post-marketing non-solicited/Spontaneous
reports
•Clinical reports
•Special reports (Medico-legal and Literature)
•Related sources
Case Processing
48. Regulatory Reporting Timelines For ICSRs
ICSR reporting timelines primarily vary based on the seriousness of an event and the nature of the reporter
Events Regulatory
Authority
Principal
Investigator
Ethics committee
Non-serious AE 90 Calendar days 90 Calendar days Periodic Reporting
SAE and SAR 15 calendar days
and follow up with
regular Periodic
reports
15 calendar days 15 calendar days
SUSAR (LT/Fatal) 7 calendar days 15 calendar days 7 calendar days
SUSAR( Non-
fatal)
15 calendar days 15 calendar days
49. Aggregate Reporting
Also known as Periodic
Reporting, plays a key role in
the safety assessment of drugs
Aggregate reporting involves
the compilation of safety data
for a drug over a prolonged
period of time (months or
years) and submit the findings to
regulators worldwide.
Aggregate report examines and summarize all existing safety
experience with a medicinal product
Report includes risk assessment of SAEs and ADRs, pregnancy
reports, overdose and lack of efficacy reports.
It is submitted to regulators as long as the medicine is marketed
anywhere in the world and enables understanding of risk benefit
profile of product over a period of time.
50. Examples of Aggregate Reports
Post marketing Reports
Periodic Safety Update Reports
(PSURs)
Periodic Adverse (Drug)
Experience Reports (US),
Development Safety Update
Reports (DSURs),
Integrated Summaries of Safety
(US), or
Clinical Summaries of Safety (EU)
Pre marketing Reports
NDAAnnual Reports
IND annual Reports
Clinical Study Reports (CSR)